SCHEMBL2392771

SCHEMBL2392771

COC(=O)/C(=N/O)c1ccccn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
SMN1; SMN2 Q16637 7/20 0.54
RAB9A P51151 5/20 0.54
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 6/20 0.51
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
HSD17B10 Q99714 1/20 0.48
NPC1 O15118 4/20 0.48
MAPT P10636 3/20 0.48
PKM P14618 3/20 0.48
LMNA P02545 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NAPRT Q6XQN6 1/20 0.47
P4HTM Q9NXG6 1/20 0.47
POLB P06746 1/20 0.47
HPGD P15428 1/20 0.46
CDK5 Q00535 1/20 0.46
PAX8 Q06710 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29755206 1.00 KMT2A (0.55) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL2084609 1.00 KMT2A (0.55) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL6218406 0.83 ALDH1A1 (0.52) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL4840329 0.83 ALDH1A1 (0.52) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL4840325 0.83 ALDH1A1 (0.52) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL13609700 0.80 KDM4E (0.63) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL15009569 0.79 CES2 (0.67) KMT2ASMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL3263280 0.79 LMNA (0.59) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL22559238 0.79 LMNA (0.59) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1
SCHEMBL3263278 0.79 LMNA (0.59) KMT2AMEN1SMN1; SMN2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114072207-B Bicyclic compounds 维瓦斯治疗公司 2024-03-29 CN disclosed
US-20220298102-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2022-09-22 US disclosed
US-11384049-B2 2022-07-12 US disclosed
US-20200347009-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. 2020-11-05 US disclosed
WO-2020214734-A1 BICYCLIC COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2020-10-22 WO disclosed
EP-2225238-B1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INT (DE) 2014-09-03 EP disclosed
US-8552205-B2 Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-08 US disclosed
US-20110224188-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-09-15 US disclosed
EP-2225238-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES Boehringer Ingelheim International GmbH (DE) 2010-09-08 EP disclosed
WO-2009070485-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224188-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES HPGDS, COL14A1, ARG1 KMT2A 2995/4885MEN1 4830/4885SMN1; SMN2 3828/4885
US-20220298102-A1 BICYCLIC COMPOUNDS YAP1, TEAD2, TEAD3 KMT2A 2248/4885MEN1 2739/4885SMN1; SMN2 3337/4885
US-11384049-B2 YAP1, HRAS, TFEB KMT2A 2768/4885MEN1 2503/4885SMN1; SMN2 2955/4885
US-20200347009-A1 BICYCLIC COMPOUNDS YAP1, TEAD2, TEAD3 KMT2A 2248/4885MEN1 2739/4885SMN1; SMN2 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.